Get the Stockscreener App
5.21
12.77%
+0.59
Orchestra BioMed Holdings Inc stock is currently priced at $5.21, with a 24-hour trading volume of 36,058.
It has seen a +12.77% increased in the last 24 hours and a +12.77% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.72 pivot point. If it approaches the $5.11 resistance level, significant changes may occur.
Previous Close:
$4.62
Open:
$4.68
24h Volume:
36,058
Market Cap:
$186.46M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-4.4175
EPS:
-1.1794
Net Cash Flow:
$-46.21M
1W Performance:
+10.62%
1M Performance:
+12.77%
6M Performance:
-23.27%
1Y Performance:
-73.42%
1D Range:
$4.68
$5.40
52W Range:
$4.22
$20.19
Orchestra BioMed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra BioMed Holdings Inc
Sector
Industry
Phone
215 862 5797
Address
150 Union Square Drive, New Hope
Orchestra BioMed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
Orchestra BioMed Holdings Inc Stock (OBIO) Latest News
Chardan Capital Comments on Orchestra BioMed Holdings, Inc.'s FY2024 Earnings (NASDAQ:OBIO) - MarketBeat
MarketBeat
Orchestra BioMed Unveils Q1 2024 Financial Results, Advances Pivotal Studies on Innovative Medical Therapies - MyChesCo
MyChesCo
Orchestra BioMed reports Q1 EPS (38c) with items, consensus (40c) - TipRanks.com - TipRanks
TipRanks
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Canada Finance
Yahoo Canada Finance
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
GlobeNewswire
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Yahoo Finance
Orchestra BioMed Holdings Inc Stock (OBIO) Financials Data
Orchestra BioMed Holdings Inc (OBIO) Revenue 2024
OBIO reported a revenue (TTM) of $2.76 million for the quarter ending December 31, 2023, a -21.88% decline year-over-year.
Orchestra BioMed Holdings Inc (OBIO) Net Income 2024
OBIO net income (TTM) was -$49.12 million for the quarter ending December 31, 2023, a -46.16% decrease year-over-year.
Orchestra BioMed Holdings Inc (OBIO) Cash Flow 2024
OBIO recorded a free cash flow (TTM) of -$46.20 million for the quarter ending December 31, 2023, a -54.64% decrease year-over-year.
Orchestra BioMed Holdings Inc (OBIO) Earnings per Share 2024
OBIO earnings per share (TTM) was -$1.50 for the quarter ending December 31, 2023, a -41.10% decline year-over-year.
About Orchestra BioMed Holdings Inc
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
0.77%
1.20%
Cap:
|
Volume (24h):